Advanced Search

Project: Pre-Exposure Prophylaxis for the Prevention of HIV Infection [Entered Retrospectively]

Public Report Complete



Project Summary

Title and Description


Key Questions


Associated Extraction Forms

Title Created by Key Questions Addressed Form Notes
Key Questions 1-5 Sara Grusing 1, 2, 3, 4, 5


Associated Studies (each link opens a new tab)

Title Author Year
Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception. Heffron R., Mugo N., Were E., Kiarie J., Bukusi EA., Mujugira A., Frenkel LM., Donnell D., Ronald A., Celum C., Baeten JM. 2014
Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. Liu AY., Vittinghoff E., Sellmeyer DE., Irvin R., Mulligan K., Mayer K., Thompson M., Grant R., Pathak S., O'Hara B., Gvetadze R., Chillag K., Grohskopf L., Buchbinder SP. 2011
Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial. Mandala J., Nanda K., Wang M., De Baetselier I., Deese J., Lombaard J., Owino F., Malahleha M., Manongi R., Taylor D., Van Damme L. 2014
Daily oral emtricitabine/tenofovir preexposure prophylaxis and herpes simplex virus type 2 among men who have sex with men. Marcus JL., Glidden DV., McMahan V., Lama JR., Mayer KH., Liu AY., Montoya-Herrera O., Casapia M., Hoagland B., Grant RM. 2014
Renal function of participants in the Bangkok tenofovir study--Thailand, 2005-2012. Martin M., Vanichseni S., Suntharasamai P., Sangkum U., Mock PA., Gvetadze RJ., Curlin ME., Leethochawalit M., Chiamwongpaet S., Cherdtrakulkiat T., Anekvorapong R., Leelawiwat W., Chantharojwong N., McNicholl JM., Paxton LA., Kittimunkong S., Choopanya K. 2014
Bone Mineral Density Changes Among Young, Healthy African Women Receiving Oral Tenofovir for HIV Preexposure Prophylaxis. Mirembe BG., Kelly CW., Mgodi N., Greenspan S., Dai JY., Mayo A., Piper J., Akello CA., Kiweewa FM., Magure T., Nakabiito C., Marrazzo JM., Chirenje ZM., Riddler SA. 2016
Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial. Mugo NR., Hong T., Celum C., Donnell D., Bukusi EA., John-Stewart G., Wangisi J., Were E., Heffron R., Matthews LT., Morrison S., Ngure K., Baeten JM. -- Not Found --
Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial. Mugwanya KK., Wyatt C., Celum C., Donnell D., Mugo NR., Tappero J., Kiarie J., Ronald A., Baeten JM. 2015
Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial. Mulligan K., Glidden DV., Anderson PL., Liu A., McMahan V., Gonzales P., Ramirez-Cardich ME., Namwongprom S., Chodacki P., de Mendonca LM., Wang F., Lama JR., Chariyalertsak S., Guanira JV., Buchbinder S., Bekker LG., Schechter M., Veloso VG., Grant RM. 2015
Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. Solomon MM., Lama JR., Glidden DV., Mulligan K., McMahan V., Liu AY., Guanira JV., Veloso VG., Mayer KH., Chariyalertsak S., Schechter M., Bekker LG., Kallás EG., Burns DN., Grant RM. 2014
Pre-exposure prophylaxis does not affect the fertility of HIV-1-uninfected men. Were EO., Heffron R., Mugo NR., Celum C., Mujugira A., Bukusi EA., Baeten JM. 2014
Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis. Lehman DA., Baeten JM., McCoy CO., Weis JF., Peterson D., Mbara G., Donnell D., Thomas KK., Hendrix CW., Marzinke MA., Frenkel L., Ndase P., Mugo NR., Celum C., Overbaugh J., Matsen FA. 2015
CD4(+) cell count, viral load, and drug resistance patterns among heterosexual breakthrough HIV infections in a study of oral preexposure prophylaxis. Chirwa LI., Johnson JA., Niska RW., Segolodi TM., Henderson FL., Rose CE., Li JF., Thigpen MC., Matlhaba O., Paxton LA., Brooks JT. 2014
HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial. Deutsch MB., Glidden DV., Sevelius J., Keatley J., McMahan V., Guanira J., Kallas EG., Chariyalertsak S., Grant RM. 2015
Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial. Murnane PM., Celum C., Mugo N., Campbell JD., Donnell D., Bukusi E., Mujugira A., Tappero J., Kahle EM., Thomas KK., Baeten JM. 2013
High medication adherence during periconception periods among HIV-1-uninfected women participating in a clinical trial of antiretroviral pre-exposure prophylaxis. Matthews LT., Heffron R., Mugo NR., Cohen CR., Hendrix CW., Celum C., Bangsberg DR., Baeten JM. 2014
Are Centers for Disease Control and Prevention Guidelines for Preexposure Prophylaxis Specific Enough? Formulation of a Personalized HIV Risk Score for Pre-Exposure Prophylaxis Initiation. Beymer MR., Weiss RE., Sugar CA., Bourque LB., Gee GC., Morisky DE., Shu SB., Javanbakht M., Bolan RK. 2017
Development and validation of the San Diego Early Test Score to predict acute and early HIV infection risk in men who have sex with men. Hoenigl M., Weibel N., Mehta SR., Anderson CM., Jenks J., Green N., Gianella S., Smith DM., Little SJ. 2015
Assessing the Performance of 3 Human Immunodeficiency Virus Incidence Risk Scores in a Cohort of Black and White Men Who Have Sex With Men in the South. Jones J., Hoenigl M., Siegler AJ., Sullivan PS., Little S., Rosenberg E. 2017
Preexposure prophylaxis guidelines have low sensitivity for identifying seroconverters in a sample of young Black MSM in Chicago. Lancki N., Almirol E., Alon L., McNulty M., Schneider JA. 2018
Prediction of HIV acquisition among men who have sex with men. Menza TW., Hughes JP., Celum CL., Golden MR. 2009
Development of a clinical screening index predictive of incident HIV infection among men who have sex with men in the United States. Smith DK., Pals SL., Herbst JH., Shinde S., Carey JW. 2012
A Brief Screening Tool to Assess the Risk of Contracting HIV Infection Among Active Injection Drug Users. Smith DK., Pan Y., Rose CE., Pals SL., Mehta SH., Kirk GD., Herbst JH. -- Not Found --
Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study. Grant RM., Mannheimer S., Hughes JP., Hirsch-Moverman Y., Loquere A., Chitwarakorn A., Curlin ME., Li M., Amico KR., Hendrix CW., Anderson PL., Dye BJ., Marzinke MA., Piwowar-Manning E., McKinstry L., Elharrar V., Stirratt M., Rooney JF., Eshleman SH., McNicholl JM., van Griensven F., Holtz TH. 2018
The acceptability and feasibility of an HIV preexposure prophylaxis (PrEP) trial with young men who have sex with men. Hosek SG., Siberry G., Bell M., Lally M., Kapogiannis B., Green K., Fernandez MI., Rutledge B., Martinez J., Garofalo R., Wilson CM. 2013
Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx Study. Liu A., Glidden DV., Anderson PL., Amico KR., McMahan V., Mehrotra M., Lama JR., MacRae J., Hinojosa JC., Montoya O., Veloso VG., Schechter M., Kallas EG., Chariyalerstak S., Bekker LG., Mayer K., Buchbinder S., Grant R. 2014
Estimating efficacy in a randomized trial with product nonadherence: application of multiple methods to a trial of preexposure prophylaxis for HIV prevention. Murnane PM., Brown ER., Donnell D., Coley RY., Mugo N., Mujugira A., Celum C., Baeten JM. 2015
Retention in care outcomes for HIV pre-exposure prophylaxis implementation programmes among men who have sex with men in three US cities. Chan PA., Mena L., Patel R., Oldenburg CE., Beauchamps L., Perez-Brumer AG., Parker S., Mayer KH., Mimiaga MJ., Nunn A. 2016
Medication Adherence in a Nationwide Cohort of Veterans Initiating Pre-exposure Prophylaxis (PrEP) to Prevent HIV Infection. van Epps P., Maier M., Lund B., Howren MB., Beck B., Beste L., Skolnik A., Vaughan-Sarrazin M., Ohl ME. 2018
Adherence to Pre-Exposure Prophylaxis for HIV Prevention in a Clinical Setting. Montgomery MC., Oldenburg CE., Nunn AS., Mena L., Anderson P., Liegler T., Mayer KH., Patel R., Almonte A., Chan PA. 2016
High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration project. Cohen SE., Vittinghoff E., Bacon O., Doblecki-Lewis S., Postle BS., Feaster DJ., Matheson T., Trainor N., Blue RW., Estrada Y., Coleman ME., Elion R., Castro JG., Chege W., Philip SS., Buchbinder S., Kolber MA., Liu AY. 2015
HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. Donnell D., Baeten JM., Bumpus NN., Brantley J., Bangsberg DR., Haberer JE., Mujugira A., Mugo N., Ndase P., Hendrix C., Celum C. 2014
Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Grant RM., Anderson PL., McMahan V., Liu A., Amico KR., Mehrotra M., Hosek S., Mosquera C., Casapia M., Montoya O., Buchbinder S., Veloso VG., Mayer K., Chariyalertsak S., Bekker LG., Kallas EG., Schechter M., Guanira J., Bushman L., Burns DN., Rooney JF., Glidden DV. 2014
Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial. Celum C., Morrow RA., Donnell D., Hong T., Hendrix CW., Thomas KK., Fife KH., Nakku-Joloba E., Mujugira A., Baeten JM. 2014
Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. Grohskopf LA., Chillag KL., Gvetadze R., Liu AY., Thompson M., Mayer KH., Collins BM., Pathak SR., Oʼhara B., Ackers ML., Rose CE., Grant RM., Paxton LA., Buchbinder SP. 2013
Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials. Agot K., Taylor D., Corneli AL., Wang M., Ambia J., Kashuba AD., Parker C., Lemons A., Malahleha M., Lombaard J., Van Damme L. 2015
The impact of adherence to preexposure prophylaxis on the risk of HIV infection among people who inject drugs. Martin M., Vanichseni S., Suntharasamai P., Sangkum U., Mock PA., Leethochawalit M., Chiamwongpaet S., Curlin ME., Na-Pompet S., Warapronmongkholkul A., Kittimunkong S., Gvetadze RJ., McNicholl JM., Paxton LA., Choopanya K. 2015
Tenofovir-based preexposure prophylaxis for HIV infection among African women. Marrazzo JM., Ramjee G., Richardson BA., Gomez K., Mgodi N., Nair G., Palanee T., Nakabiito C., van der Straten A., Noguchi L., Hendrix CW., Dai JY., Ganesh S., Mkhize B., Taljaard M., Parikh UM., Piper J., Mâsse B., Grossman C., Rooney J., Schwartz JL., Watts H., Marzinke MA., Hillier SL., McGowan IM., Chirenje ZM. 2015
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. Baeten JM., Donnell D., Ndase P., Mugo NR., Campbell JD., Wangisi J., Tappero JW., Bukusi EA., Cohen CR., Katabira E., Ronald A., Tumwesigye E., Were E., Fife KH., Kiarie J., Farquhar C., John-Stewart G., Kakia A., Odoyo J., Mucunguzi A., Nakku-Joloba E., Twesigye R., Ngure K., Apaka C., Tamooh H., Gabona F., Mujugira A., Panteleeff D., Thomas KK., Kidoguchi L., Krows M., Revall J., Morrison S., Haugen H., Emmanuel-Ogier M., Ondrejcek L., Coombs RW., Frenkel L., Hendrix C., Bumpus NN., Bangsberg D., Haberer JE., Stevens WS., Lingappa JR., Celum C. 2012
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Choopanya K., Martin M., Suntharasamai P., Sangkum U., Mock PA., Leethochawalit M., Chiamwongpaet S., Kitisin P., Natrujirote P., Kittimunkong S., Chuachoowong R., Gvetadze RJ., McNicholl JM., Paxton LA., Curlin ME., Hendrix CW., Vanichseni S. 2013
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. Grant RM., Lama JR., Anderson PL., McMahan V., Liu AY., Vargas L., Goicochea P., Casapía M., Guanira-Carranza JV., Ramirez-Cardich ME., Montoya-Herrera O., Fernández T., Veloso VG., Buchbinder SP., Chariyalertsak S., Schechter M., Bekker LG., Mayer KH., Kallás EG., Amico KR., Mulligan K., Bushman LR., Hance RJ., Ganoza C., Defechereux P., Postle B., Wang F., McConnell JJ., Zheng JH., Lee J., Rooney JF., Jaffe HS., Martinez AI., Burns DN., Glidden DV. 2010
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. Molina JM., Capitant C., Spire B., Pialoux G., Cotte L., Charreau I., Tremblay C., Le Gall JM., Cua E., Pasquet A., Raffi F., Pintado C., Chidiac C., Chas J., Charbonneau P., Delaugerre C., Suzan-Monti M., Loze B., Fonsart J., Peytavin G., Cheret A., Timsit J., Girard G., Lorente N., Préau M., Rooney JF., Wainberg MA., Thompson D., Rozenbaum W., Doré V., Marchand L., Simon MC., Etien N., Aboulker JP., Meyer L., Delfraissy JF. 2015
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. Thigpen MC., Kebaabetswe PM., Paxton LA., Smith DK., Rose CE., Segolodi TM., Henderson FL., Pathak SR., Soud FA., Chillag KL., Mutanhaurwa R., Chirwa LI., Kasonde M., Abebe D., Buliva E., Gvetadze RJ., Johnson S., Sukalac T., Thomas VT., Hart C., Johnson JA., Malotte CK., Hendrix CW., Brooks JT. 2012
Preexposure prophylaxis for HIV infection among African women. Van Damme L., Corneli A., Ahmed K., Agot K., Lombaard J., Kapiga S., Malahleha M., Owino F., Manongi R., Onyango J., Temu L., Monedi MC., Mak'Oketch P., Makanda M., Reblin I., Makatu SE., Saylor L., Kiernan H., Kirkendale S., Wong C., Grant R., Kashuba A., Nanda K., Mandala J., Fransen K., Deese J., Crucitti T., Mastro TD., Taylor D. 2012
Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial. Kibengo FM., Ruzagira E., Katende D., Bwanika AN., Bahemuka U., Haberer JE., Bangsberg DR., Barin B., Rooney JF., Mark D., Chetty P., Fast P., Kamali A., Priddy FH. 2013
Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. Mutua G., Sanders E., Mugo P., Anzala O., Haberer JE., Bangsberg D., Barin B., Rooney JF., Mark D., Chetty P., Fast P., Priddy FH. 2012
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. McCormack S., Dunn DT., Desai M., Dolling DI., Gafos M., Gilson R., Sullivan AK., Clarke A., Reeves I., Schembri G., Mackie N., Bowman C., Lacey CJ., Apea V., Brady M., Fox J., Taylor S., Antonucci S., Khoo SH., Rooney J., Nardone A., Fisher M., McOwan A., Phillips AN., Johnson AM., Gazzard B., Gill ON. 2016
Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. Peterson L., Taylor D., Roddy R., Belai G., Phillips P., Nanda K., Grant R., Clarke EE., Doh AS., Ridzon R., Jaffe HS., Cates W. 2007
Plasma Tenofovir Levels to Support Adherence to TDF/FTC Preexposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California. Landovitz RJ., Beymer M., Kofron R., Amico KR., Psaros C., Bushman L., Anderson PL., Flynn R., Lee DP., Bolan RK., Jordan WC., Tseng CH., Dierst-Davies R., Rooney J., Wohl AR. 2017
Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services. Liu AY., Cohen SE., Vittinghoff E., Anderson PL., Doblecki-Lewis S., Bacon O., Chege W., Postle BS., Matheson T., Amico KR., Liegler T., Rawlings MK., Trainor N., Blue RW., Estrada Y., Coleman ME., Cardenas G., Feaster DJ., Grant R., Philip SS., Elion R., Buchbinder S., Kolber MA. 2016
Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States. Hosek SG., Landovitz RJ., Kapogiannis B., Siberry GK., Rudy B., Rutledge B., Liu N., Harris DR., Mulligan K., Zimet G., Mayer KH., Anderson P., Kiser JJ., Lally M., Brothers J., Bojan K., Rooney J., Wilson CM. 2017
An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM. Hosek SG., Rudy B., Landovitz R., Kapogiannis B., Siberry G., Rutledge B., Liu N., Brothers J., Mulligan K., Zimet G., Lally M., Mayer KH., Anderson P., Kiser J., Rooney JF., Wilson CM. 2017




Creative Commons LicenseThis graphic notice indicates that you are leaving this Federal Government Web site and entering a non-Federal Web site. Creative Commons  
The data contained in this project are distributed under the terms of the Creative Commons Attribution-NonCommerical license, which permits the use, dissemination, and reproduction in any medium, provided the original work is properly cited, and that the use is non-commercial and otherwise in compliance with the license. See: https://creativecommons.org/licenses/by-nc/3.0/